Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | ItovebiTM (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant - (INAVO120) | HR-Positive Advanced Breast Cancer | Phase 3 | Data Released | Oral | Oncology |
| Roche Holding AG ADR | Vabysmo (faricimab-svoa) - (ELEVATUM) | Diabetic macular edema (DME) | Phase 3 | Data Released | Intravitreal injection | Opthalmic |
| Roche Holding AG ADR | Xofluza (baloxavir marboxil) - (CENTERSTONE) | Influenza viruses | Phase 3 | Data Released | Oral | Antiviral |
| Roche Holding AG ADR | Vabysmo - (BALATON) | Macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) | Phase 3 | Data Released | Intravitreal | Opthalmic |
| Roche Holding AG ADR | Amezalpat (TPST-1120) with atezolizumab and bevacizumab - (TPST-1120-301) | Hepatocellular carcinoma (HCC) | Phase 3 | Trial Planned | Intravenous | Oncology |
| Roche Holding AG ADR | Evrysdi (risdiplam) - (RAINBOWFISH) | Babies with pre-symptomatic spinal muscular atrophy (SMA) | Phase 3 | Data Released | Oral | Genetic Disorder |
| Roche Holding AG ADR | Venclexta + azacitidine - (VERONA) | 1L high risk Myelodysplastic Syndromes (MDS) | Phase 3 | Trial Completed | oral and intravenous | Hematology |
| Roche Holding AG ADR | Crovalimab - (COMMODORE 3) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Intravenous | Hematology |
